share_log

Stocks of the Hour: Spenda, Cettire, Immutep

Stocks of the Hour: Spenda, Cettire, Immutep

時下股票:Spenda、Cettire、Immutep
sharecafe ·  2023/05/16 09:30

Building upon a 20-year commercial foundation, Capricorn Society has selected Spenda (ASX:SPX) as its preferred supplier to deliver the first phase of its Digital Service Delivery initiative. Spenda's CEO and MD Adrian Floate, added: "Being selected to work with Capricorn on this significant project shows faith in both in our services and in our ability to deliver to Capricorn's vision." Shares are flat at 1.2 cents.

在20年的商業基礎上,Capricorn Society已選擇Spenda (ASX: SPX) 作爲其首選供應商,以交付其數字服務交付計劃的第一階段。Spenda的首席執行官兼總經理Adrian Floate補充說:“被選中與Capricorn合作開展這個重要項目,這表明了對我們的服務以及我們實現摩羯座願景的能力的信心。”股價持平至1.2美分。

Global luxury online retailer, Cettire (ASX:CTT), provided a trading update, in which sales revenue shot up 122%, versus prior corresponding period. Cettire's Founder and CEO, Dean Mintz, said: "It is particularly pleasing to see the Company's localisation strategy is delivering results, with revenue from its emerging markets outpacing the Group." Shares are trading 12.06 per cent higher at $2.09.

全球奢侈品在線零售商Cettire (ASX: CTT) 提供了最新交易數據,銷售收入與前同期相比增長了122%。Cettire的創始人兼首席執行官迪恩·明茨表示:“特別令人高興的是,該公司的本地化戰略正在取得成果,其新興市場的收入超過了集團。”股價上漲12.06%,至2.09美元。

Immutep (ASX:IMM) receives positive feedback from FDA regarding the Company's late-stage clinical development plans for its first-in-class soluble LAG-3 protein. Immutep CEO, Marc Voigt, commented: "this meeting with the FDA is a critical step in our late-stage development process for 1st line non-small cell lung cancer." Shares are trading 2.22 per cent higher at 23 cents.

Immutep (ASX: IMM) 收到了美國食品藥品管理局關於該公司首創可溶性 LAG-3 蛋白的後期臨床開發計劃的積極反饋。Immutep首席執行官馬克·沃伊特評論說:“這次與美國食品藥品管理局的會晤是我們一線非小細胞肺癌後期開發過程中的關鍵一步。”股價上漲2.22%,至23美分。

1x1.png?futu_img_keep_extra_domain=1

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論